IRFF Breakthroughs:
Pioneering Plasmalogen-Based Therapies for Brain Health

Our institute is at the forefront of innovative research into plasmalogens and their derivatives, exploring their remarkable potential to improve memory in Alzheimer’s disease (AD) patients and mitigate brain neuroinflammation. Oral intake of scallop Plasmalogens showed potential therapeutic benefits among patients with AD. In addition, Our recent groundbreaking studies have identified promising plasmalogen derivatives—such as KIT-13 and KIT-20—which have demonstrated significant therapeutic effects in both Rett syndrome and Leight model mice. These compounds have even received Orphan Drug Designation (ODD) from the FDA, underscoring their potential to revolutionize treatment paradigms.

In parallel, our team has developed state-of-the-art software tools for genomics, transcriptomics, and gut microbiome studies. These cutting-edge platforms empower researchers to investigate disease-related genomic alterations and identify novel drug targets with unprecedented precision.

Moreover, our advanced bio-behavioral tracking systems—designed for mice and C. elegans—utilize machine learning (ML) and AI technologies to accurately assess the therapeutic impacts of new drug candidates.
By integrating these innovative tools created by IRFF, we are accelerating the discovery of bioactive molecules that could pave the way for a healthier, and brighter future.

Join us as we push the boundaries of biomedical research, transforming promising scientific discoveries into real-world solutions for complex health challenges.